Gland Pharma Ltd Q1 FY26: USFDA’s Favourite Child or Just Another Overpriced Syringe? 💉💸

1. At a Glance

Injectables are hot, but Gland Pharma’s stock is hotter—P/E 43x, ROE just 7.8%. The Hyderabad-based company clocked Q1 FY26 sales of ₹1,506 crore (+7.4% YoY) and PAT of ₹215 crore (+49.9% YoY). Market cap? ₹33,300 crore. Promoter? China’s Fosun Pharma, holding 52%. If you think this is “Made in India,” think again—it’s more “Made in India, Owned in Shanghai, Injected in the US.”

2. Introduction

Imagine you’re a pharma nerd. You’ve spent years hearing about Cipla’s generics, Sun Pharma’s Taro acquisition, Dr. Reddy’s Russia adventures. Then comes Gland Pharma—quietly selling syringes, vials, and injectables to 60+ countries. From Hyderabad’s back alleys in 1978, it has grown into a global injectables powerhouse, with plants in India, France, and Belgium.

But there’s drama: margins slipped from 34% in FY22 to 24% in FY24, thanks to the Cenexi acquisition. R&D spends dropped from 5% of revenue in FY22 to just 3% now (penny-pinching much?). And yet, USFDA approvals keep pouring in like monsoon potholes—Cangrelor, Vasopressin, Angiotensin II, Norepinephrine, Latanoprostene, Acetaminophen… basically half the ICU shelf.

Question: When the FDA loves you but investors think your ROE is weaker than SBI’s savings account, what wins?

3. Business Model – WTF Do They Even Do?

Simple but scale-heavy:

• B2B (98%): Contract manufacturing, dossier compilation, tech transfer. Basically, the white-label king of injectables.
• B2C (2%): Only in India. Supplies to 4,000+ hospitals. Small, but shows up at investor calls for “India story” masala.

Product basket = 89+ SKUs, spanning oncology, ophthalmology, dry powders, infusions, lyophilized vials, pre-filled syringes. Injectables are tricky, high-barrier, capital-heavy. That’s why Gland can survive—few want to touch this space.

Geographical split = US 54%, Europe 18% (boosted post-Cenexi), India 5%, RoW 20%. So basically, Uncle Sam pays the bills, EU adds glamour, and India is the pocket change.

4. Financials Overview

Commentary: Strong profit growth despite only modest sales rise. Annualized EPS = ₹52. At CMP ₹2,022, forward P/E ~39x. Premium pricing for not-so-premium ROE.

5. Valuation Discussion – Fair Value Range

Method 1: P/E

• EPS annualized = ₹52
• Apply fair P/E 25–35x (peer band: Cipla ~23x, Torrent ~59x) → ₹1,300 – ₹1,800

Method 2: EV/EBITDA

• FY25 EBITDA ~₹1,372 Cr
• EV = ₹31,098 Cr → EV/EBITDA ~22x
• Peer